Resolve Your Uncertainty
ThyroidPrint® predicts whether an indeterminate thyroid nodule is benign or not with high diagnostic accuracy allowing to avoid diagnostic surgery.
GeneproDX® presents ThyroidPrint®, a molecular diagnostic tool streamlining the management of indeterminate thyroid nodules (Bethesda III/IV). This fifteen year long research output redefines nodules as Benign or Malignancy Suspicious, boosting patient care decisions. GeneproDX® is accredited by College of American Pathologists (No. 1821095).
Thyroidprint clinical pathway in case of thyroid nodule detection
How does ThyroidPrint® work?
ThyroidPrint was developed to predict benignity of indeterminate thyroid nodules using an innovative microfluidics real-time PCR technology and a neural network-based algorithm analysis.
It provides the following performance parameters:
ensitivity 91%, Specificity 88%, Negative Predictive Value 95% and positive Predictive Value of 78%
GeneproDX & Biocartis
First-of-its-kind Molecular Test:
Analyzed in Your Hospital in Less Than 3 Hours
Thanks to the partnership between GeneproDx® and Biocartis™, ThyroidPrint® becomes the world’s only decentralized molecular test for thyroid nodules through the Idylla™ platform.
It will be available soon in Europe (Q4 2023), allowing hospitals to conduct the analysis directly on-site.
Come and discover this groundbreaking innovation that will revolutionize diagnosis at our booth during the WCTC 2023 from June 15th to 17th in London, UK. We will be located at booth n° 19.
Growing World Presence
Scientific evidence
ThyroidPrint®, globally validated in hundreds of patients, including those from the USA, ensures consistent and top-quality results. We invite you to download and delve deeper into the studies that support our test, which have been recognized in reputable publications such as the Thyroid Journal. These studies demonstrate the rigorous scientific research and proven clinical value of our test.
Clinical Validation
This publication is reports two-independent multicenter – prospective trials that validate the clinical performance of ThyroidPrint® in two- ethnically diverse cohorts
Test Design & Statistical Rational
This review addresses the statistical rational supporting the intended use of molecular testing for indeterminate thyroid nodules.
Biomarker Discovery & Development
This paper provides the insight on the biomarker discovery process and classifier development to reach a statistical performance necessary to serve the intended use of ThyroidPrint® (Rule-out).
Independent Comment by Expert
This publication is a summary and comment by an independent expert about the clinical validation studies of ThyroidPrint®
Independent Comment by Expert
This publication is a summary and comment by an independent expert about the biomarker discovery & development of ThyroidPrint®
Clinical Utility
This publication reports the first real-world experience with ThyroidPrint®, showing the impact on physician decision making and the resulting benefit for patients tested with ThyroidPrint®
Visit us at booth N° 19 at the WCTC 2023 from June 15th- 17th in London, UK
